Shasun Pharmaceuticals has moved higher by over 5% to Rs 68.90 in otherwise subdued market after the company said it has entered into a licensing agreement with a Swiss-based Debiopharm Group for the manufacturing and commercialization of Huperzine-A.
According to the terms of the agreement, Shasun Pharmaceuticals will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets, Shasun Pharma said in a press release.
Huperzine-A is a potent and reversible acetyl cholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance patents with Alzheimer’s disease.
The stock opened at Rs 65.65 and touched high of Rs 69.80 on BSE. A combined 332,625 shares have changed hands on the counter till 1157 hours on BSE and NSE.
According to the terms of the agreement, Shasun Pharmaceuticals will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets, Shasun Pharma said in a press release.
Huperzine-A is a potent and reversible acetyl cholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance patents with Alzheimer’s disease.
The stock opened at Rs 65.65 and touched high of Rs 69.80 on BSE. A combined 332,625 shares have changed hands on the counter till 1157 hours on BSE and NSE.
